MedPath

Management of Moderately Hypoxemic Thoracic Trauma

Not Applicable
Active, not recruiting
Conditions
High Flow Oxygenation
Chest Trauma
Interventions
Device: Standard oxygen
Device: High flow Oxygenation
Registration Number
NCT03997630
Lead Sponsor
University Hospital, Brest
Brief Summary

In France, the average incidence of thoracic trauma is 10,000 to 15,000 each year. These patients are at risk of early and late post traumatic respiratory complications as follows: pneumonia, Acute Respiratory Distress Syndrome (ARDS), hypoxemia. Main issues of thoracic trauma management were recently published by French anesthesiologist and intensivist experts. Non-invasive ventilation (NIV) was recommended in case of severe hypoxemia (PaO2/FiO2 \< 200). In comparison to conventional oxygenation or mechanical ventilation, NIV reduced length of stay, incidence of complications and mortality in case of severe hypoxemia. For mild or moderate hypoxemic patients, no devices were tested to prevent respiratory complications. At the moment, low-flow oxygenation is administered to these patients in the absence of severe hypoxemia. Recently, many studies have found promising results with high-flow oxygenation delivered by nasal cannula. This device has many physiological advantages: wash out the naso-pharyngeal dead space, increase end expiratory lung volume, deliver a moderate or low level of Positive end-expiratory pressure (PEEP), improve work of breathing and confort. Several randomized controlled trials tested this device in many clinical settings, but there are no studies on its use after thoracic trauma. A comparative trial is needed to evaluate early prophylactic administration of high-flow oxygenation after thoracic trauma.

Detailed Description

TrOMaTho study is an investigator-initiated, randomized, unblinded, controlled trial. The aim of this study is to compare a prophylactic use of high-flow nasal cannula oxygenation (experimental group) to low-flow oxygenation (control group) after thoracic trauma. 770 patients will be included. Randomization will be conducted with random block and patients will be randomized in 1:1 ratio in one of the two groups. Randomization process will be stratified on: age (more or less 65 years old), use of peridural analgesia and existence of extra thoracic trauma. Only the oxygenation technique is studied, all other aspects of management will be handle by the attending physician.

All patients will be followed from enrollment to hospital discharge. To ensure the same data collection in all centers, six visits are planned: day (D) 1 (inclusion), D7, D14, D28.

Classical blinded methods cannot be used for the evaluation of these kinds of devices. To ensure the same evaluation for all patients and in all centers, all relevant outcomes will be evaluated by an independent clinical event committee. Statistical analysis will be performed by an independent statistician.

Primary endpoint will be analyzed according to intention to treat. Secondary outcomes will be analyzed as exploratory analysis.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
770
Inclusion Criteria
  • Major patient (age ≥ 18 years),
  • Admitted to intensive care unit for less than 48 hours for the management of chest trauma.
  • Closed chest trauma, non-penetrating, with a TTSS score> or equal to 4.
  • Need for conventional oxygen therapy to maintain SpO2 greater than or equal to 95%.
  • Patient affiliated or beneficiary of a social security scheme
  • Patient having signed a consent
Exclusion Criteria
  • Severe hypoxemia defined as a PaO2/FiO2 ratio < 200 noted before randomization

  • Recommended indication for NIV: cardiogenic pulmonary oedema, decompensated COPD.

  • Indication to immediate oro-tracheal intubation. (will not be excluded patients requiring general anaesthesia for a surgical procedure for a peripheral surgical procedure or embolization)

    • Patient with acute respiratory distress, whatever the cause.
    • Hemodynamic instability marked by a fall of the PAS> 30% or a PAS <110 mmHg despite the initial resuscitation measures
    • Neurological degradation with Glasgow score less than 12
  • Pregnant or lactating woman

  • Patient under guardianship or curatorship

  • Contraindication to the use of one or both devices studied (decaying facial trauma)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Control groupStandard oxygenControl group: All patients included in this group will receive a low flow oxygenation (flow rate \< 15 l/min) with nasal cannula (flow rate ≤ 6 l/min) or non-rebreathing mask (flow rate ≥ 7 l/min).
Interventional groupHigh flow OxygenationInterventional group: All patients included in this group will receive a continuous heated and humidified high-flow (30 to 60 l/min) oxygenation with a nasal cannula for 48 hours. Initially, flow rate will be started at 50 l/min with a FiO2 at 50%. According to the protocol, flow rate and FiO2 will be titrated on SpO2 and respiratory tolerance. Weaning and failure of high-flow oxygenation are described in detail in the study protocol.
Primary Outcome Measures
NameTimeMethod
safety eventDay 28

The primary endpoint is a composite endpoint defined by:

* The use of non-invasive ventilation whatever the cause before the 14th day following the trauma (yes/no) OR

* The use of orotracheal intubation whatever the cause before the 14th day following on the thoracic traumatism.(yes/no) OR

* The death any cause confused with D28. (yes/no)

Secondary Outcome Measures
NameTimeMethod
Severe hypoxemiaday 14

Severe hypoxemia before day 14: SpO2 \< 92% or PaO2/FiO2 \< 200 without oxygenation

Respiratory tract infectionday 14

Respiratory tract infection before day 14 defined according to international recommendations on health-associated pneumonia or trachea-bronchitis.

Mechanical ventilationday 14

Need for mechanical ventilation before day 14. Criteria used to define the need of mechanical ventilation is an acute respiratory distress defined as: the inability to clear tracheal secretion, a deterioration of neurological status (decrease in GCS of 2 points), a respiratory acidosis (pH \< 7,25 and PaCO2 \> 45 mmHg), signs of persisting or worsening respiratory failure (respiratory rate \> 35/min, high respiratory-muscle workload) with a poor response to another oxygenation device.

oxygen free daysday 14

number of day without oxygen

ventilator free daysday 14

number of day without ventilation

ICU length of stayday 90

number of day in ICU

All cause of mortalityday 28 or day 90

Mortality (yes/no)

Severity of dyspnea using a Saint Georges respiratory questionnaireday 90

Saint Georges questionnary total score

quality of life 3 months after High flow oxgenation with the The Short Form (36) Health Survey scoreday 90

SF 36 questionnary total score

Hospital length of stayday 90

number of day of the total stay in hospital

Trial Locations

Locations (18)

Centre Hospitalier de Cornouaille

🇫🇷

Quimper, Bretagne, France

Angers university hospital

🇫🇷

Angers, France

CHU de Brest

🇫🇷

Brest, France

Chartres Hospital

🇫🇷

Chartres, France

HIA Percy

🇫🇷

Clamart, France

Dreux hospital

🇫🇷

Dreux, France

Le Mans hospital

🇫🇷

Le Mans, France

Centre Hospitalier de Bretagne Sud

🇫🇷

Lorient, France

CHRU de Montpellier

🇫🇷

Montpellier, France

Morlaix hospital

🇫🇷

Morlaix, France

La Timone Hospital (AP-HM)

🇫🇷

MArseille, France

Marseille university horpital

🇫🇷

Marseille, France

Nantes university hospital

🇫🇷

Nantes, France

CHRU de la Pitié-Salpétrière

🇫🇷

Paris, France

Kremlin Bicêtre university hospital (APHP)

🇫🇷

Paris, France

Rennes, university Hospital

🇫🇷

Rennes, France

Tours university hospital

🇫🇷

Tours, France

CHBA de Vannes

🇫🇷

Vannes, France

© Copyright 2025. All Rights Reserved by MedPath